Slide 10. Secondary CHD prevention in women: results from the CARE trial

The CARE trial included 576 (14%) women, whose mean HDL-C at baseline was 45 mg/dl, which is borderline low for women.  Pravastatin significantly reduced combined coronary events (coronary death, nonfatal myocardial infarction, percutaneous transluminal coronary angioplasty [PTCA], and coronary artery bypass grafting [CABG]) by 45% and PTCA by 48%; reductions in CABG and stroke were substantial but were not statistically significant.

Reference:

Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau JL, Pfeffer MA, Braunwald E, for the CARE investigators. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 1998;32:140-146.